Why the study?
Does heparin bridging and different timing of rivaroxaban interruption/resumption affect perioperative complications in patients undergoing catheter ablation for atrial fibrillation?
Does heparin bridging and different timing of rivaroxaban interruption/resumption affect perioperative complications in patients undergoing catheter ablation for atrial fibrillation?
In patients undergoing catheter ablation for atrial fibrillation, heparin bridging increases non-major bleeding risk, and stopping rivaroxaban 8-28 hours before with resumption within 12 hours appears safe.
May support avoiding heparin bridging in AF ablation; leaves open optimal rivaroxaban timing pending randomized trials.
No takes yet. Share an insight, caveat, or question.
Hirao et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: